I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Presentation of Cantargia’s report for the second quarter of 2022

August 30th, 3.00 PM CEST

Cantargia R&D Day on nadunolimab featuring Prof Van Cutsem and Dr Paz-Ares

CEO presentation AGM

To the presentation (In Swedish)

Panel discussion business development

To Panel discussion

CEO Interview

To the interview (In Swedish)

CEO interview

To the interview (in Swedish)

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)

Press releases

2022-09-22 (R) Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy

2022-09-15 (R) Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence

2022-09-13 (R) Cantargia presents preclinical data demonstrating unique treatment effects of nadunolimab on pancreatic cancer stromal cells

(R) = Regulatory press releases

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg

CEO Cantargia

Analysis

2022-09-02, Aktiespararna analysis of Cantargia (In Swedish)

2022-08-31, Edison analysis of Cantargia

2022-08-31, Redeye analysis of Cantargia

2022-08-31, Nordea analysis of Cantargia

Presentations

2022-08-30 Presentation, Cantargia Q2 Report

2022-08-24, Video, Erik Penser Banks Company Day (In Swedish)

2022-08-24, Presentation, Erik Penser Banks Company Day

2022-06-02, Presentation, Redeye Growth Day

© Copyright 2022 · Cantargia AB